Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a single-institution experience
- PMID: 17207238
- DOI: 10.1111/j.1537-2995.2007.01071.x
Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a single-institution experience
Abstract
Background: Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) is a diagnosis of exclusion when a patient presents with the sine qua non findings of thrombocytopenia and microangiopathic hemolytic anemia without an identifiable cause. Although most patients respond to therapeutic plasma exchange (TPE), a significant number of patients relapse. The aim was to determine if clinical, laboratory, and/or treatment features could predict response and/or relapse.
Study design and methods: This study was a retrospective review of adults with TTP-HUS treated with TPE at our institution from January 1996 to February 2004.
Results: The study population consisted of 90 patients (69% female) with mean age of 45 years and mostly obese (65%). The majority of cases were considered idiopathic. Ten patients died (11%) from the disease before achieving a response, whereas 79 percent were considered responders. Obesity and severe anemia at presentation were predictors of response to TPE (p = 0.0126 and p = 0.0071, respectively). Among the responders, 28 percent relapsed in a median of 14 months. Male sex, severe thrombocytopenia (mean +/- SD, 13 x 10(9) +/- 8 x 10(9)/L), and higher lactate dehydrogenase pre-/posttreatment ratio were associated with relapse (p values of 0.0141, 0.0199, and 0.0407, respectively). ADAMTS-13 values were not obtained on enough number of patients to provide important data.
Conclusion: Although patient and laboratory characteristics associated with response and relapse were identified, there was significant overlap between patient groups. Thus, our findings offer preliminary evidence and do not yet justify short- or long-term changes in the management of patients with TTP-HUS.
Similar articles
-
Frequency and significance of schistocytes in TTP/HUS patients at the discontinuation of plasma exchange therapy.J Clin Apher. 2004;19(4):165-7. doi: 10.1002/jca.20017. J Clin Apher. 2004. PMID: 15597353
-
Treatment outcomes in patients with adult thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.Arch Intern Med. 1994 May 9;154(9):982-7. Arch Intern Med. 1994. PMID: 8179455
-
Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome: a new index predicting response to plasma exchange.Br J Haematol. 2006 Jan;132(2):204-9. doi: 10.1111/j.1365-2141.2005.05857.x. Br J Haematol. 2006. PMID: 16398654 Clinical Trial.
-
Pathophysiology and management of thrombotic microangiopathies.J Nephrol. 1998 Nov-Dec;11(6):300-10. J Nephrol. 1998. PMID: 10048496 Review.
-
Thrombotic microangiopathy: current knowledge and outcomes with plasma exchange.Semin Dial. 2012 Mar-Apr;25(2):214-9. doi: 10.1111/j.1525-139X.2011.01035.x. Epub 2012 Feb 7. Semin Dial. 2012. PMID: 22309967 Review.
Cited by
-
Outcomes of Immune Thrombotic Thrombocytopenic Purpura (iTTP) With Upfront Cyclophosphamide vs. Rituximab.Front Med (Lausanne). 2020 Oct 28;7:588526. doi: 10.3389/fmed.2020.588526. eCollection 2020. Front Med (Lausanne). 2020. PMID: 33195351 Free PMC article.
-
Effect of Blood Groups on Clinical Presentations and Treatment Outcomes in Immune Thrombotic Thrombocytopenic Purpura Patients with Severe ADAMTS13 Deficiency: A Multi-Center Experience.Transfus Med Hemother. 2022 Jun 10;50(1):18-25. doi: 10.1159/000524597. eCollection 2023 Feb. Transfus Med Hemother. 2022. PMID: 36818771 Free PMC article.
-
Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase.Ther Adv Hematol. 2022 Jul 26;13:20406207221112217. doi: 10.1177/20406207221112217. eCollection 2022. Ther Adv Hematol. 2022. PMID: 35923772 Free PMC article. Review.
-
ADAMTS13 activity and antigen during therapy and follow-up of patients with idiopathic thrombotic thrombocytopenic purpura: correlation with clinical outcome.Haematologica. 2011 Oct;96(10):1521-7. doi: 10.3324/haematol.2011.042945. Epub 2011 May 23. Haematologica. 2011. PMID: 21606162 Free PMC article.
-
Successful treatment with Rituximab in a patient with life-threatening resistant Thrombotic Thrombopenic Purpura.Hippokratia. 2012 Oct;16(4):388. Hippokratia. 2012. PMID: 23935329 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources